金融界9月25日消息，国药控股发布2024年中期报告，报告期内，公司实现收入294,726.81百万元，较上年同期下降2.07%，达到溢利人民币5,899.22百万元，较上年同期下降14.42%。同期，公司实现母公司持有者应占溢利人民币3,703.88百万元，比上年同期减少400.56百万元，同比下降9.76%。每股盈利为1.19元，比上年同期下降9.85%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.